| __timestamp | ADMA Biologics, Inc. | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 31073000 |
| Thursday, January 1, 2015 | 6745968 | 43216000 |
| Friday, January 1, 2016 | 8494742 | 50679000 |
| Sunday, January 1, 2017 | 18092835 | 79171000 |
| Monday, January 1, 2018 | 22502922 | 168218000 |
| Tuesday, January 1, 2019 | 25910757 | 210796000 |
| Wednesday, January 1, 2020 | 35050817 | 203613000 |
| Friday, January 1, 2021 | 42896889 | 234273000 |
| Saturday, January 1, 2022 | 52458024 | 265784000 |
| Sunday, January 1, 2023 | 59020000 | 344501000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and ADMA Biologics, Inc. over the past decade. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reaching approximately $344 million in 2023. In contrast, ADMA Biologics saw a more modest increase of around 1,100%, with expenses peaking at nearly $59 million in the same year. This stark difference highlights Insmed's aggressive expansion strategy, while ADMA Biologics maintains a more conservative approach. Understanding these trends provides valuable insights into each company's operational priorities and financial health. As the biotech industry continues to evolve, monitoring such financial metrics will be key to predicting future growth and sustainability.
Eli Lilly and Company vs ADMA Biologics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or ADMA Biologics, Inc.
Insmed Incorporated vs Halozyme Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Insmed Incorporated and Pharming Group N.V.
Insmed Incorporated and Opthea Limited: SG&A Spending Patterns Compared
Insmed Incorporated and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Blueprint Medicines Corporation vs ADMA Biologics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and PTC Therapeutics, Inc.
ADMA Biologics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and MorphoSys AG
ADMA Biologics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and MiMedx Group, Inc.